[go: up one dir, main page]

MX2020008387A - Usos terapeuticos de agonistas glp1r. - Google Patents

Usos terapeuticos de agonistas glp1r.

Info

Publication number
MX2020008387A
MX2020008387A MX2020008387A MX2020008387A MX2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A
Authority
MX
Mexico
Prior art keywords
glp1r
certain
aspects
disclosure provides
agonists
Prior art date
Application number
MX2020008387A
Other languages
English (en)
Inventor
Jennifer L R Freeman
Lopez Maria Carmen Valcarce
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2020008387A publication Critical patent/MX2020008387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los métodos para usar agonistas de receptor de péptido 1 similar al glucagón (GLP1R) se describen en general en la presente. En ciertos aspectos, la descripción proporciona métodos para tratar diabetes tipo 2 que incluyen administrar un agonista GLP1R de acuerdo con ciertos regímenes de dosis. En ciertos aspectos diferentes, la descripción proporciona métodos para tratar obesidad que incluyen administrar un agonista GLP1R de acuerdo con ciertos regímenes de dosis. En ciertos aspectos diferentes, la descripción proporciona métodos para disminuir hemoglobina glicada (por ejemplo, disminuir HbAlc} que incluyen administrar un agonista GLP1R de acuerdo con ciertos regímenes de dosis. Las composiciones que contienen agonistas GLP1R y su manufactura, por ejemplo, para uso como un medicamento también se describen en la presente.
MX2020008387A 2018-05-08 2019-05-01 Usos terapeuticos de agonistas glp1r. MX2020008387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862668384P 2018-05-08 2018-05-08
PCT/US2019/030110 WO2019217165A1 (en) 2018-05-08 2019-05-01 Therapeutic uses of glp1r agonists

Publications (1)

Publication Number Publication Date
MX2020008387A true MX2020008387A (es) 2020-12-11

Family

ID=66484210

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008387A MX2020008387A (es) 2018-05-08 2019-05-01 Usos terapeuticos de agonistas glp1r.

Country Status (10)

Country Link
US (1) US20210023072A1 (es)
EP (1) EP3790549A1 (es)
JP (2) JP2021523877A (es)
KR (1) KR20210005843A (es)
AU (2) AU2019266114A1 (es)
CA (1) CA3090823A1 (es)
MX (1) MX2020008387A (es)
SG (1) SG11202007966UA (es)
TW (1) TW202015683A (es)
WO (1) WO2019217165A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11702404B2 (en) * 2019-10-25 2023-07-18 Gilead Sciences, Inc. GLP-1R modulating compounds
US12121511B2 (en) 2020-01-29 2024-10-22 Gilead Sciences, Inc. GLP-1R modulating compounds
CN115461344B (zh) * 2020-04-01 2024-01-12 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
WO2021196951A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
WO2021238962A1 (zh) * 2020-05-28 2021-12-02 杭州中美华东制药有限公司 一种制备glp-1受体激动剂的方法
EP4213847A4 (en) * 2020-09-21 2024-12-04 vTv Therapeutics LLC AMORPHOUS FORM OF AN ISOQUINOLINE DERIVATIVE
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304712A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022225941A1 (en) 2021-04-21 2022-10-27 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1147094A1 (en) * 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
CN101959405B (zh) 2008-03-07 2014-07-02 转化技术制药有限责任公司 治疗糖尿病的氧杂二氮杂蒽化合物
BRPI1013579A2 (pt) 2009-03-30 2020-11-03 Transtech Pharma, Inc. derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
EA201491749A1 (ru) * 2012-03-22 2015-01-30 ТРАНСТЕК ФАРМА, ЭлЭлСи Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение
WO2014113357A1 (en) * 2013-01-17 2014-07-24 Transtech Pharma, Llc Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders

Also Published As

Publication number Publication date
KR20210005843A (ko) 2021-01-15
CA3090823A1 (en) 2019-11-14
US20210023072A1 (en) 2021-01-28
AU2019266114A1 (en) 2020-08-27
TW202015683A (zh) 2020-05-01
AU2025201814A1 (en) 2025-04-03
JP2024112903A (ja) 2024-08-21
JP2021523877A (ja) 2021-09-09
EP3790549A1 (en) 2021-03-17
WO2019217165A1 (en) 2019-11-14
SG11202007966UA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
MX2020008387A (es) Usos terapeuticos de agonistas glp1r.
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
MX2023008854A (es) Agonistas del receptor acoplado a proteinas g (gpcr), composiciones farmaceuticas que los comprenden y metodos para su uso.
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2023001980A (es) Derivado de imidazol fusionado, metodo de preparacion y uso medico del mismo.
NZ732000A (en) Gip and glp-1 co-agonist compounds
TN2017000148A1 (en) Co-agonists of the glucagon and glp-1 receptors
SA522431576B1 (ar) مركبات مساعدة لمستقبل بشري لبولي ببتيد مفرز للإنسولين يتوقف على الجلوكوز
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MY191321A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
PH12015500194A1 (en) Fusion proteins for treating a metabolic syndrome
EA201001801A1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
PH12017501222B1 (en) Glucagon derivatives with improved stability
MX2021005945A (es) Ureas ciclicas.
MX2021004930A (es) Analogos de proteina tirosina-tirosina y metodos de uso de esta.
MX2009013779A (es) Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r.
MX2024010346A (es) Compuestos como agonistas de glp-1r.
MX2022011089A (es) Peptidos como agonistas selectivos del receptor de gip.
PH12012500895A1 (en) Method for treating heart failure with stresscopin-like peptides
SA522432563B1 (ar) نظير ببتيد أوكسينتو موديولين معالج بأسيل
MX366685B (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
MX2019011867A (es) Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva.
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
MX2024002845A (es) Nuevos peptidos como agonistas potentes y selectivos del receptor de gip.